argenx SE ADR ARGX 深 滬
等待開盤 12-17 09:30:00 美东时间
851.42
+0.470
+0.06%
華盛通- 最 高858.435
- 今 開853.99
- 成交量 34.47万股
- 最 低 842.205
- 昨 收 850.95
- 總市值 524.21亿
- 52周最高 934.6199
- 市盈率 靜 66.73
- 換手率 0.00%
- 52周最低 510.055
- 委 比 -66.98%
- 總股本 6156.89万
- 歷史最高 934.6199
- 量 比 0.90
- 振 幅 1.91%
- 歷史最低 19.00
- 每 手 1
- 風險率 109.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘后 | Elanco Animal Health涨3.13%，Guardant Health涨2.66%
Elanco Animal Health涨3.13%；Guardant Health涨2.66%；加拿大皇家银行涨2.34%
12-16 07:11
Argenx, Navan And 3 Stocks To Watch Heading Into Monday
Stock futures up, focus on HYFT, ARGX, NAVN, AXR, CSBR as they report earnings. Top 2 energy stocks to watch for potential plunge this month.
12-15 15:42
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Wells Fargo Maintains Overweight on argenx, Raises Price Target to $1316
Wells Fargo analyst Derek Archila maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1095 to $1316.
12-12 01:11
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1110
Morgan Stanley analyst Matthew Harrison maintains argenx (NASDAQ:ARGX) with a Overweight and raises the price target from $1070 to $1110.
12-04 23:10
Looking Into argenx SE's Recent Short Interest
argenx SE's (NYSE:ARGX) short interest as a percent of float has fallen 8.96% s...
11-28 23:00
This Argenx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a comple...
11-24 20:49
Wolfe Research Downgrades argenx to Peer Perform
Wolfe Research analyst Andy Chen downgrades argenx (NASDAQ:ARGX) from Outperform to Peer Perform.
11-24 19:00
